DURHAM, N.C., Sept. 24 /PRNewswire/ -- Argos Therapeutics  today announced that results from its Arcelis™  immunotherapy Phase 2 study for the treatment of renal cell carcinoma (RCC) have been accepted for a poster presentation at the Ninth International Kidney Cancer Symposium on Oct. 1-2 in Chicago.
The study is an open-label Phase 2 trial that enrolled 25 patients with newly diagnosed metastatic clear cell RCC. Post-nephrectomy, subjects received sunitinib and then concomitant AGS-003. The first endpoint was to evaluate clinical activity as measured by objective tumor response, and the secondary endpoints included safety, clinical activity via estimates of progression free survival, overall survival and assessment of clinical benefit as measured by stable disease, partial response, and CR rates and measurement of immune response.
About the Arcelis™ Technology 
Arcelis is Argos' proprietary technology for personalizing RNA-loaded dendritic cell immunotherapies for cancer, HIV and other infectious diseases. This platform is based on optimizing a patient's own (autologous) dendritic cells to trigger a tumor- or pathogen-specific immune response. To address the challenge of the unique genetic profile of each patient's disease and the genetic mutations of that disease, Argos loads the autologous dendritic cells with a sample of messenger RNA ("mRNA") isolated from the patient's disease. Through this process, dendritic cells can potentially prime immune responses to the entire antigenic repertoire, resulting in an immunotherapeutic that is customized to the patient's specific disease.
About Argos Therapeutics, Inc.Argos is an immunotherapy company developing new treatments for cancer, infectious and autoim